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The article describes the amination of different monobromo-
or monochloroflavones with primary and secondary alk-
ylamines and aniline derivatives by Buchwald–Hartwig reac-
tion. The influence of the phosphine ligands used is de-
Introduction
Benzopyran derivatives with amino functionalities are a
very important class of oxygen-containing heterocycles, and
many of them have remarkable biological activity. Chrom-
one and flavone alkaloids without a direct link between the
aromatic/heteoaromatic ring and the amine nitrogen are
natural products, and their occurrence and chemistry have
been reviewed.[1] Rohitukine, a chromone alkaloid isolated
from Disoxylum binectifarum and Amoora rohituka, inhibits
cyclin-dependent kinase (CDK).[2] Its semisynthetic ana-
logue, flavopiridol (Alvocidib, HMR 1275, L86–8275, NSC
649890) is an antineoplastic agent, inhibiting CDK1,
CDK2, CDK4, CDK5, CDK6, and CDK9 kinases; it has
been studied alone and in combinations in phase I and II
clinical trials (Scheme 1).[3]
The other important subclass of amine-containing
benzopyran derivatives consists of chromones and flavones
in which the nitrogen is directly attached to an aromatic sp2
carbon. 7-Aminoflavone was found to show antibacterial
effects against, among others, M. tuberculosis strains.[4,5] 6-
Amino-5,7-dihydroxyflavone showed outstanding activity
in the low micromolar range as an α-glucosidase inhibitor.[6]
Many aminoflavones belonging to this second subclass
have shown considerable cytotoxic, kinase inhibitory, or
antiproliferative effects. 4-Aminoflavones with one or more
hydroxy groups in their A-ring have shown tyrosine-kinase
inhibitory effect against p56lck, an enzyme of 56 kDa. The
most active derivative was 4-amino-6-hydroxyflavone.[7a]
5,7,4-Triamino-6-hydroxyflavone selectively inhibited
p56lck, while 6,4-diamino-7-hydroxyflavone and 5,7,3-tri-
amino-6-hydroxyflavone were more or less active against
EGFr and p60v–src.[7b] 5,4-Diaminoflavone, 5-amino-4-di-
methylaminoflavone, and 6-amino-4-(dimethylamino)flav-
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scribed. The use of amino acid derivatives as a nitrogen
source is also demonstrated. This latter reaction allows the
synthesis of unique flavone–amino-acid conjugates.
one have shown considerable antiproliferative effects
against the MCF-7 breast-cancer cell line.[8] 4-Amino-6- or
7-fluoroisoflavones showed moderate antitumor effects
against MDA-MB-468, MCF-7, HT29, and HCT-116 cell
lines.[9] The aminoflavone-based peptide NSC 710464 (AFP
464)[10] is considered to be an anticancer prodrug. It is in
phase I clinical trials, and it seems to be useful against solid
tumors (Scheme 1).[11]
3-Amino-4-methoxyflavone and 3,3-diamino-4-meth-
oxyflavone showed remarkable cytotoxicity aginst L1210
leukemia cells, and their 3-(diethylaminoethyl)amino ana-
logues showed activities similar to those of the parent 3-
aminoflavones.[12] T-614, a 3-formamidochromone deriva-
tive, showed anti-inflammatory, antiarthritic, and oral anti-
rheumatic effects.[13] 3-(N-Alkylureido)chromone and 3-
(N-alkylureido)-1-thiochromone selectively inhibited the
v-abl tyrosine kinase.[14]
However, methods for the synthesis of aminochromones
and flavones suffer from limitations, particularly for those
derivatives with amine substituents in the A-ring. The most
common synthetic methods are based on a Claisen–
Schmidt condensation or a Baker–Venkataraman re-
arrangement (Scheme 2). In the first case, a base-induced
aldol-type condensation gives a chalcone 2, which, in turn,
can be cyclised into a nitro- or acetamidoflavone 3.[15–21]
The same intermediates (i.e., 3) are accessible by aroylation
followed by Baker–Venkataraman rearrangement under
strongly basic conditions.[7b,8,22–27] The desired aminoflav-
ones (i.e., 4) can be obtained by reduction or hydrolysis.
The latter transformation usually requires harsh conditions
(Scheme 2). The major problem with these methods is the
synthesis of the appropriate acetophenone (i.e., 1), which is
limited by the regioselectivity of the nitration of aceto-
phenone, and by the sensitivity of the R1 substituents under
the harsh conditions.
Alternatively, a previously constructed flavone moiety
can also be nitrated and then submitted to reduction, but
the reactivity and selectivity patterns of the nitration step
are also limiting factors.[7b,28,29] The Wessely–Moser re-
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Scheme 1.
Scheme 2.
arrangement is a special route to aminoflavones.[6,28,30] The
synthesis of alkyl/arylamino or disubstituted amino deriva-
tives represents a much greater challenge. Direct alkylation
suffers from a lack of selectivity, which leads to low
yields.[8,15] Alkylation of an acetamido or sulfonylamido
group followed by the cleavage of the protecting group has
been reported.[9,28] Reductive alkylation,[31,32] and direct
aromatic nucleophilic substitution of an aromatic triflyloxy
group under microwave conditions[33] have also been de-
scribed.
The synthesis of 3-aminoflavones 7 can be carried out by
the reduction of 3-nitro 8[12,16,34–37] or 3-oximino derivatives
9, or from 3-azidoflavanones 10 under basic condi-
tions.[38–40] Reduction of the nitro group has been carried
out by catalytic hydrogenation.[12,34,41,42] 3-Oximinoflavan-
ones 9 gave also 3-aminoflavones 7 upon treatment with
tin(II) chloride (Scheme 3).[43,44]
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Sasaki, Miyake, and their coworkers published the syn-
thesis of various 3-alkylaminoflavones from 3-bromoflav-
ones,[45a] 3-tosyloxyflavones, or 3-mesyloxyflavones,[45b] but
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the structural assignment of their products proved to be
wrong (vide infra).
In recent decades, Buchwald–Hartwig amination of halo-
substituted aromatic/heteroaromatic systems has become
the method of choice for the synthesis of alkyl- and aryl-
amino substituted arenes.[46] Surprisingly, only sporadic ex-
amples have been published in the field of oxygen hetero-
cycles. There are only two published examples of the prepa-
ration of amino derivatives: the synthesis of 7-amino-5-
hydroxyflavone started from a triflate,[47] while 4-aminoiso-
flavone was prepared from the corresponding bromide.[12]
Caddick and his coworkers reported the Buchwald–Hart-
wig reaction of bromo- or triflyloxy-substituted flavones
under microwave activation, but they only used hexylamine
as the nitrogen source.[48] This astonishing gap in the amin-
ation of oxygen heterocycles prompted us to start a system-
atic investigation of the scope and limitations of this
method. We present our first results in this paper.
Results and Discussion
We started our studies using the conditions of Caddick’s
group,[48] but a much wider variety of primary and second-
ary aliphatic and aromatic amines were tested. It turned out
that microwave activation has no beneficial effect; reactions
using conventional thermal heating show the same effi-
ciency. Reactions of 6-bromoflavone (11) with various
amines in the presence of Pd2(dba)3 (dba = dibenzylidene-
acetone) as a palladium source resulted in the formation of
the desired 6-aminoflavones (i.e., 12a–12p; Scheme 4,
Table 1). The only limiting factor is steric hindrance in the
reacting amine. Increasing the number of α-branchings
clearly decreases the yield (Table 1, entries 1–4). A similar
effect was also observed in the reactions of 7-bromoflavone
(17; vide infra). The lower yield for the reaction with dibut-
ylamine in comparison with the cyclic secondary amines
(Table 1, entry 10 vs. entries 11–14) also supports the role
of bulkiness.
Scheme 4.
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Table 1. Amination of 6-bromoflavone (11).
Entry Product R1 R2 Yield [%][a]
1 12a Bu H 46[b]
2 12b iBu H 46
3 12c sBu H 38
4 12d tBu H 0[c,d]
5 12e Bn H 59
6 12f cHex H 57
7 12g 2-Me-C6H4 H 53
8 12h 4-Cl-C6H4 H 48
9 12i 4-MeO-C6H4 H 75
10 12j Bu Bu 18
11 12k –(CH2)4– 40
12 12l –(CH2)5– 58
13 12m –(CH2)2O(CH2)2– 51
14 12n –(CH2)2Me(CH2)2– 73
15 12o Ph Me 31
16 12p 1,2,3,4-tetrahydroquinolin-1-yl 48
[a] Yields refer to pure isolated products. [b] N,N-Bis(flavon-6-yl)-
butylamine (14; 11%) was also isolated. [c] Traces of the expected
product could be detected by TLC. [d] Flavone (13; 7.7%) and β-
diketone 15 (15%) were isolated. These by-products were also de-
tected by TLC in several other reactions.
In all cases, flavone (13) was detected or isolated as a by-
product. Competitive reductive elimination and β-hydride
elimination from the organopalladium intermediate may
both take place to reform the catalyst, but the latter path-
way gives a dehalogenated product, i.e., flavone (13), which
results in a decrease of the yield of the aminated product.
In the reaction of substrate 11 with butylamine, an interest-
ing bis-arylated product 14 was also obtained in low (11%)
yield. Obviously, here the Buchwald–Hartwig product acts
as the amine in a second cross-coupling reaction. Surpris-
ingly, no similar double Buchwald–Hartwig coupling was
observed with any of the other amines tested. It is note-
worthy that Caddick and his coworkers[48] also mentioned
the formation of a similar diflavonoid tertiary amine deriva-
tive starting from 4-bromo-2-chloro-6-methylflavone and
hexylamine. In some cases, we also observed the formation
of 5-bromo-2-hydroxydibenzoylmethane (and its tauto-
meric form) (15). The appearance of this by-product under
the strictly water-free conditions used can be explained by
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Scheme 6. Structures of the ligands used.
a concurrent ring-opening of the heterocycle: the tert-
butoxide anion attacks the electrophilic C-2 atom of the
flavone moiety, and the intermediate enol ether (i.e., 16)
hydrolyses during aqueous work-up and column chroma-
tography on silica (Scheme 5).
Next, we investigated the role of the phosphine ligands
and their effect on the yield of the cross-coupling reaction.
6-Bromoflavone (11) was treated with butylamine, cyclohex-
ylamine, or piperidine in the presence of various phosphines
A–I (Scheme 6) keeping all the other reagents the same, but
using microwave activation. The amount of the 6-(di)substi-
tuted aminoflavone product (i.e., 12a, 12f, or 12l) was deter-
mined by HPLC. The results are summarised in Table 2,
and they clearly show that there is no “magic” ligand with
outstanding efficiency for every model amine. The best
yields were achieved using electron-rich monodentate biaryl
ligands, particularly ligands B, C, and E.
The average HPLC yields were 45%, but there were
large deviations. For example, ligand I gave good results
with primary amines, but only a low HPLC yield with the
secondary amine piperidine. We can conclude that many of
these ligands can be used successfully, but a detailed op-
timisation is needed in each case.
We chose 7-bromoflavone (17) as our next substrate to
allow a comparison of the reactivity of the 6- and 7-posi-
tions. We have previously demonstrated the higher reactiv-
ity of the 7-position in Heck–Mizoroki reactions.[49] Brom-
ide 17 was treated with various amines under the same con-
ditions as described above (Scheme 7, Table 3). The reac-
tions were successful with all the tested acyclic and cyclic
aliphatic amines as well as aniline derivatives, and the yields
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Table 2. Efficiency of the amination of 6-bromoflavone (11) in the
presence of different phosphine ligands.[a]
HPLC area [%][b]
Ligand BuNH2 cHexNH2 Piperidine
A 1 3 15
B 45 51 79
C 43 35 61
D 28 15 6
E 41 43 60
F 29 30 28
G 31 29 55
H 38 27 57
I 75 43 24
[a] Reaction conditions: Pd2(dba)3 (5 mol-%), ligand (7.5 mol-%),
NaOtBu (1.4 equiv.), amine (1.2 equiv.), dry toluene, MW (110 °C),
15 min. [b] Product ratios were determined by HPLC; Pinnacle II
C18 column, 1504.6 mm, MeOH/H2O (gradient).
were either similar to or better than those obtained with 6-
bromoflavone (11). This observation was consistent with
our expectations: the electronic effect of a carbonyl group
in the para position usually speeds up palladium-catalysed
cross-coupling reactions. We can assume that the rate-de-
Scheme 7.
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termining step of this amination is the oxidative addition,
i.e., the insertion of palladium(0) into the C–Br bond.
Table 3. Amination of 7-bromoflavone (17).
Entry Product R1 R2 Yield [%][a]
1 18a Bu H 81
2 18b iBu H 79
3 18c sBu H 79
4 18d tBu H 28
5 18e Bn H 89
6 18f 4-Cl-C6H4 H 55
7 18g 4-MeO-C6H4 H 74
8 18h Bu Bu 16
9 18i –(CH2)4– 79
10 18j –(CH2)5– 55
11 18k –(CH2)2O(CH2)2– 74
12 18l Ph Me 41
[a] Yields refer to pure isolated products.
We also compared the reactions of 6- and 7-haloflavones
containing different halogen atoms under our standard con-
ditions. Consistent with our expectations, bromoflavones 11
and 17 gave much higher yields than the corresponding 6-
chloro (21) and 7-chloro (22) derivatives (Table 4). This dif-
ference can be explained on the basis of the higher acti-
vation energy of the oxidative addition step of the shorter
and stronger C–Cl bond, and the electronic effect of the
carbonyl group in the para position.
Table 4. Isolated yields from the Buchwald–Hartwig reactions of
6/7-bromo- and -chloroflavones 11, 17, 21, and 22 with various
amines.
Yield [%][a]
Amine 6-Br (11) 7-Br (17) 6-Cl (21) 7-Cl (22)
BuNH2 46 81 7.7 32
BnNH2 59 89 8.8 41
Pyrrolidine 40 79 7.3 38
4-Cl-C6H4 48 55 6.5 36
[a] Yields refer to pure isolated products.
Next, we tested the amination of 7-bromo-4-meth-
oxyflavone (19) with some model primary and secondary
amines (Scheme 7). No significant differences could be ob-
served in the yields of the coupled products. The distant
substituent does not exert any significant electronic effect
(see Supporting Information).
Next, we studied the possible Buchwald–Hartwig reac-
tion of 3-bromoflavone (23) under our previously optimised
conditions, since the number of methods that have been re-
ported for the preparation of 3-alkyl/arylaminoflavones or
related systems is very limited (vide supra). Unfortunately,
this coupling reaction gave the expected amines (i.e., 24) in
much lower yields than those obtained with the bromides
studied earlier (i.e., 11, 17, and 19), particularly with sec-
ondary amines (Scheme 8, Table 5). The use of microwave
activation did not change the outcome of the coupling reac-
tions (Table 5, entry 2). Typically, reductive elimination
leading to flavone (13) took place to a considerable extent.
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We can conclude that this method, although it seems to
work, has only limited synthetic value for the preparation
of mono- or alkylated/arylated 3-aminoflavone derivatives.
Scheme 8.
Table 5. Synthesis of 3-aminoflavone derivatives 24 by Buchwald–
Hartwig reaction.
Entry Product R1 R2 Yield [%][a] Yield of 13 [%][a]
1 24a Bu H 33 14
2[b] 24a Bu H 27 n.d.
3 24b Hex H 23 n.d.
4 24c Bn H 56 9
5 24d –(CH2)4– 13 17
6 24e –(CH2)5– 6 26
7 24f 4-Me-C6H4 H 26 n.d.
[a] Yields refer to pure isolated products; n.d.: not determined.
[b] Reaction carried out under MW irradiation (110 °C, 15 min,
200 W).
Earlier both Caddick’s group[48] and Miyake’s group[45]
reported the synthesis of 3-alkylaminoflavones from 3-
bromo-, 3-tosyloxy-, or 3-mesyloxyflavones. Caddick and
his coworkers[51] treated 3-bromoflavone (23) with hex-
ylamine under microwave irradiation, but in the presence of
Pd(OAc)2 instead of Pd2(dba)3 used previously. However,
our 1H and 13C NMR spectroscopic data were completely
different from those reported by them in their Supplemen-
tary Information. The major problem with the assignment
of the right structure is that the heterocyclic product con-
tains only quaternary carbons, which makes the ring size
questionable. Miyake and his coworkers also reported the
synthesis of 3-amino- or 3-(alkylamino)flavones in good or
excellent yields by simply treating 3-bromo-, 3-(tosyloxy)-,
or 3-(mesyloxy)flavones with ammonia or with primary
amines in THF solution at room temperature, but they did
not present any m.p. values or spectroscopic data.[45] There-
fore, we tested their reaction conditions by treating 3-
bromoflavone (23) with butylamine and hexylamine in THF
without any palladium source. The isolated products had
identical or similar spectral data to “3-hexylaminoflavone”
reported by Caddick et al. The spectral data indicated the
presence of the same groups, thus, our Buchwald–Hartwig
products and the Caddick/Miyake products should be
structural isomers; one of them is the expected 3-(alk-
ylamino)flavone, while the other is 2-[α-(alkylamino)benzyl-
idene]benzofuran-3(2H)-one, a product of a ring-contrac-
tion. Significant differences could be found between the 1H
NMR data of our Caddick/Miyake products and our Buch-
wald–Hartwig products. The Caddick/Miyake products
showed NH signals at δ = 10 ppm, signals of the hydrogen
in the peri position to the carbonyl group at δ = 7.84 ppm,
and NCH2 signals at δ ≈ 3.22 ppm. The corresponding
values for our Buchwald–Hartwig products were δ ≈ 4.4,
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Scheme 9.
8.25, and 2.64 ppm, respectively. The 13C NMR signals dif-
fered less markedly. We carried out 2D NMR spectroscopic
measurements (COSY and HMBC) for both of the butyl-
substituted compounds to assign the signals of the carbon
and hydrogen atoms (see Supporting Information). HMBC
measurements showed a strong cross-peak between the 1-
H (NCH2) and Cα signals in the spectrum of the Caddick/
Miyake product. On the other hand, the cross-peak be-
tween the 1-H (NCH2) and C-3 signals in our Buchwald–
Hartwig product clearly proved that Caddick/Miyake prod-
uct should be 2-[α-(butylamino)benzylidene]benzofuran-
3(2H)-one (25a).
The formation of the ring-contracted products (i.e., 25a
and 25b) can be explained in terms of attack of the amine
nucleophile on the C-2 atom of the oxygen heterocycle
(Scheme 9).
To obtain additional and independent proof for the
structure of 3-(butylamino)flavone (24a) obtained in the
Buchwald–Hartwig procedure, and to rule out isomeric
structure 25a, we alkylated the parent 3-aminoflavone (i.e.,
26) with butyl bromide in aqueous solution in the presence
of potassium carbonate under microwave irradiation using
the protocol developed for 3-(N,N-alkylamino)flavones.[50]
The resulting product showed the same spectroscopic data
as our Buchwald–Hartwig product, thus proving that the
structures of Caddick’s and Miyake’s compounds were
erroneously assigned.
We also investigated the synthesis of N-unsubstituted
aminoflavones. The most frequently used ammonia equiva-
lents in Buchwald–Hartwig cross-coupling are benzophen-
one imine[51] and lithium silyl amides.[52] Until now, only
one example has been published in the field of flavones.[47]
We successfully prepared both 6-aminoflavone (28a) and 7-
aminoflavone (28b) via the corresponding imine intermedi-
ates (i.e., 27a and 27b) in 48 and 38% overall yields, respec-
tively (Scheme 10). Unfortunately, the reaction of 3-bromo-
flavone (23) failed to give the desired 3-aminoflavone (27).
Next, we tested the cross-coupling reaction with α-amino
acid methyl esters as the nitrogen source. This reaction
could lead to hitherto almost unknown amino-acid–flavone
hybrids of potential biological importance. To the best of
our knowledge, only two examples of such derivatives have
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Scheme 10.
been published to date, and neither of them was obtained
by Buchwald–Hartwig (or Ullmann) type coupling. Korean
authors[53] prepared a conjugate by alkylation of a pre-
formed 6-aminoflavone (28a) with an α-bromo-α-phen-
ylacetic acid thioester, while Georg et al.[54] coupled 8-
amino-4-chloro-5-hydroxyflavone with N-Boc-protected
amino acids (Boc = tert-butoxycarbonyl). First, we treated
6-bromoflavone (11) with l-phenylalanine methyl ester
hydrochloride (29a), but the desired coupled product could
not be obtained under the previously used conditions.
After extensive optimisation, we found a set of conditions:
Pd2(dba)3 should be replaced by palladium(II) acetate, and
the original base sodium tert-butoxide should be replaced
by cesium carbonate. However, the expected product (i.e.,
30a) was only obtained in a very low yield (5 %), and, in
addition, the regioisomeric 7-{[2-phenyl-1-(methoxycarb-
onyl)ethyl]amino}flavone (31a) was also isolated in 6%
yield (Scheme 11). These structures were assigned on the
basis of their NMR spectra, and the constitution of com-
pound 31a was also supported by its independent synthesis
(vide infra).
A possible explanation for this astonishing observation
may be the so-called “halogen dance”[55] under the strongly
basic conditions. According to this suggested mechanism, a
deprotonation at the 7-position of the starting 6-bromoflav-
one (11) takes place, followed by a bromine exchange be-
tween the resulting carbanion intermediate and a second
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Scheme 11.
molecule of starting material to give 6,7-dibromoflavone.
The relative ease of this deprotonation may be explained by
the higher stability of this carbanion. The 6,7-dibromoflav-
one intermediate may react with the above-mentioned carb-
anion to yield 7-bromoflavone (17). These hypothetical
steps are consistent with the generally accepted mechanism
of the “halogen dance”. However, it should be emphasised
that the “halogen dance” usually needs more basic condi-
tions [LDA (dithium diisopropylamide), BuLi, NaNH2,
ArNHK, etc.]. In addition, to the best of our knowledge,
this would be the first example of such a transformation to
be observed in a Buchwald–Hartwig reaction.
Applying the same conditions to the reaction of 7-
bromoflavone (17) and various amino acid methyl ester
hydrochlorides 29, the expected products (i.e., 31a–31e)
were obtained (Scheme 11, Table 6), and no 6-substituted
products were obtained or detected. The higher reactivity
of 7-bromoflavone (17) caused by electronic effects (vide
supra) leads to a fast reaction, and so excludes the “halogen
dance”. These results further demonstrate the synthetic util-
ity of the Buchwald–Hartwig reaction in the field of oxygen
heterocycles. On the other hand, the data summarised in
Table 6 clearly show that the polarity of the amino acid has
a decisive role in the efficiency of the reaction. The coupling
with l-aspartic acid resulted in a low yield, and no product
was obtained with l-serine or l-tryptophan. The lack of
any reaction may be explained by either the low solubility
of the amino acid derivative in xylene, or by ligation of
the palladium(0)/palladium(II) ion to the heteroatom of the
reagent.
Table 6. Synthesis of flavone–amino-acid hybrids 31 by Buchwald–
Hartwig reaction.
Entry Amino acid Product Yield [%] ee [%]
1 l-Phe 31a 64 6
2 d-Phe 31a 59 10
3 l-Ala 31b 30 n.d.
4 l-Leu 31c 56 6
5 l-Met 31d 40 1
6 l-Asp 31e 11 2
7 l-Ser 31f 0 –
8 l-Trp 31g 0 –
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Another drawback of coupling with amino acid esters, at
least at the moment, is racemisation (Table 6). This can be
attributed to a deprotonation–reprotonation sequence at
the stereogenic centre of the amino acid unit.
Conclusions
In conclusion, we have demonstrated that the Buchwald–
Hartwig amination of bromoflavones with halo substituents
on their aromatic rings is a useful tool for the synthesis
of amine derivatives that are hardly available by previously
reported methods. We have pointed out that the previously
published structures of some derivatives obtained from 3-
halo- or sulfonyloxyflavones with primary amines were er-
roneously assigned, and that in fact, ring-contracted prod-
ucts were formed. Palladium-catalysed C–N bond forma-
tion also proved to be an efficient tool in the synthesis of
flavone–amino-acid hybrids, although the coupling takes
place accompanied by significant racemisation of the ste-
reogenic centre. Experiments aimed at avoiding this racem-
isation and extending the number of nitrogen sources are in
progress, and the results will be published soon.
Experimental Section
General Remarks: Column chromatography was carried out on sil-
ica gel (Merck 60, 70–230 mesh). Thin-layer chromatography was
carried out on silica gel plates 60 F254 (Merck, 0.2 mm). In phos-
phine-ligand optimisation studies, product ratios were determined
by HPLC using a Pinnacle II column (C18, 1504.6 mm, 5 μm;
MeOH/H2O, gradient: from 60 to 90% MeOH in 20 min; flow:
0.9 mL/min, 280 nm). Chiral HPLC was carried out using a Chi-
ralpak IC column (2504.6 mm) with a Jasco HPLC system: Jasco
PU-980 HPLC pump, Jasco MD-910 multiwavelength detector.
The purity of the compounds was established by GC–MS (Agilent
7890, Agilent 5975 MS detector) with positive EI at 70 eV. NMR
spectra were recorded with a Bruker AM 360 (360.13 MHz for 1H,
90.03 MHz for 13C) spectrometer. Chemical shifts (δ) were cal-
ibrated using the CHCl3 signals (δ = 7.26 ppm) for 1H and (δ =
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77.00 ppm) for 13C spectra. Melting points were determined by
using Büchi B-540 equipment. Elemental analysis (C, H) was con-
ducted with an Elementar Vario MicroCube instrument. IR spectra
were measured as KBr discs with a Jasco FTIR 4100A instrument.
Microwave-assisted reactions were carried out using a CEM-Dis-
cover Focused microwave synthesis system (2450 MHz).
6-Bromoflavone (11),[56] 7-bromoflavone (17),[56] and amino acid
methyl ester hydrochlorides[57] were synthesised according to litera-
ture procedures.
Buchwald–Hartwig Cross-Coupling by Thermal Heating: Halo-
flavone (0.66 mmol), NaOtBu (88 mg, 0.92 mmol), BINAP [2,2-
bis(diphenylphosphino)-1,1-binaphthyl; 32 mg, 0.050 mmol], and
amine (0.80 mmol) were mixed in dry toluene (6 mL) in a dried
flask under nitrogen, and Pd2(dba)3 (30 mg, 0.032 mmol) was
added. The reaction mixture was stirred at reflux for 3 h in an oil
bath. The crude reaction mixture was applied directly to a silica
gel column to give the pure cross-coupled product.
Buchwald–Hartwig Cross-Coupling by Microwave Activation: 6-
Bromoflavone (0.33 mmol), NaOtBu (44 mg, 0.46 mmol), BINAP
(15 mg, 0.025 mmol), and amine (0.80 mmol) were mixed in dry
toluene (3 mL) in a sealed vial under nitrogen, and Pd2(dba)3
(15 mg, 0.016 mmol) was added. The reaction mixture was stirred
for 15 min at 110 °C (200 W). The crude reaction mixture was ap-
plied directly to a silica gel column to give the pure cross-coupled
product.
Only representative examples are given here. Characterisation data
for the vast majority of the products are presented in the Support-
ing Information.
6-(Butylamino)flavone (12a): Eluent: toluene/ethyl acetate, 4:1; yield
88 mg (46%) from 11, 15 mg (7.7%) from 21; m.p. 124.5–126.5 °C.
1H NMR (CDCl3): δ = 7.89 (m, 2 H, 2-H, 6-H), 7.50 (m, 3 H,
3-H, 5-H, 4-H), 7.39 (d, J = 8.6 Hz, 1 H, 8-H), 7.24 (d, J =
2.5 Hz, 1 H, 5-H), 6.98 (dd, J = 2.9, 9.0 Hz, 1 H, 7-H), 6.78 (s, 1
H, 3-H), 3.87 (s, 1 H, NH), 3.19 (t, J = 7.2 Hz, 2 H, 1-H), 1.64
(m, 2 H, 2-H), 1.45 (m, 2 H, 3-H), 0.97 (t, J = 7.6 Hz, 3 H, 4-
H) ppm. 13C NMR (CDCl3): δ = 178.6 (C-4), 162.6 (C-2), 149.3
(C-8a), 146.2 (C-6), 132.2 (C-1), 131.1 (C-4), 128.9 (C-3, C-5),
126.1 (C-2, C-6), 124.8 (C-4a), 121.2 (C-7), 118.8 (C-8), 106.7 (C-
5), 103.5 (C-3), 43.9 (C-1), 31.4 (C-2), 20.2 (C-3), 13.9 (C-4)
ppm. IR (KBr): ν˜ = 3352, 2949, 2926, 2865, 1624, 1582, 1570, 1490,
1450, 1211, 912, 818, 770 cm–1. MS: m/z = 293 [M]+·, 250 (100%).
C19H19NO2 (293.36): calcd. C 77.79, H 6.53, N 4.77; found C
77.75, H 6.52, N 4.75.
N,N-Bis(2-phenyl-4-oxo-4H-chromen-6-yl)butylamine (14): Eluent:
toluene/ethyl acetate, 4:1; yield 20 mg (11%); m.p. 218–220 °C. 1H
NMR (CDCl3): δ = 7.91 (m, 4 H, 4 H), 7.81 (d, J = 2.7 Hz, 2 H),
7.53 (dd, J = 4.8, 1.1 Hz, 5 H), 7.49 (d, J = 9.1 Hz, 3 H), 7.35 (dd,
J = 9.0, 2.8 Hz, 2 H), 6.81 (s, 2 H), 3.91–3.75 (m, 2 H), 1.77–1.61
(m, 2 H), 1.42 (dd, J = 15.0, 7.5 Hz, 2 H), 0.95 (t, J = 7.3 Hz, 3
H) ppm. 13C NMR (CDCl3): δ = 178.1 (C-4), 163.1 (C-2), 151.6
(C-8a), 145.1 (C-6), 131.8 (C-1), 131.4 (C-4), 128.9 (C-3, C-5),
127.9 (C-7), 126.2 (C-2, C-6), 124.9 (C-4a), 12.2 (C-7), 119.3 (C-
8), 115.0 (C-5), 106.9 (C-3), 52.7 (C-1), 29.4 (C-2), 20.2 (C-3),
13.9 (C-4) ppm. IR (KBr): ν˜ = 3446, 3064, 2956, 2925, 2854,
1632, 1566, 1495, 1480, 1451, 1356, 1259, 910, 818, 770 cm–1. MS:
m/z = 326, 213 (100%), 137, 105, 77, 55. C34H27NO4 (513.59):
calcd. C 79.51, H 5.30, N 2.73; found C 79.70, H 5.35, N 2.75.
6-[(2-Methylphenyl)amino]flavone (12g): Eluent: toluene/ethyl acet-
ate, 4:1; yield 114 mg (53%); m.p. 220–223 °C. 1H NMR (CDCl3 +
[D6]DMSO): δ = 7.92 (m, 2 H, 2-H, 6-H), 7.61 (d, J = 2.5 Hz, 1
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H, 5-H), 7.53 (m, 3 H, 3-H, 5-H, 4-H), 7.48 (d, J = 9.0 Hz, 1 H,
8-H), 7.31 (dd, J = 2.5, 9.7 Hz, 1 H, 7-H), 7.25 (m, 2 H, 3-H, 6-
H), 7.18 (m, 1 H, 5-H), 7.01 (m, 1 H, 4-H), 6.78 (s, 1 H, 3-H),
5.88 (s, 1 H, NH), 2.27 (s, 3 H, 2-CH3) ppm. 13C NMR (CDCl3 +
[D6]DMSO): δ = 177.1 (C-4), 161.9 (C-2), 149.2 (C-8a), 142.9 (C-
1), 140.1 (C-6), 131.3 (C-2), 130.8 (C-3), 130.5 (C-4), 130.3
(C-1), 128.5 (C-3, C-5), 126.1 (C-5), 125.6 (C-2, C-6), 123.9
(C-4a), 122.8 (C-4), 122.6 (C-6), 120.7 (C-7), 118.4 (C-8), 106.9
(C-5), 105.7 (C-3), 17.6 (2-CH3) ppm. IR (KBr): ν˜ = 3317, 3113,
3063, 2939, 1641, 1619, 1576, 1534, 1483, 1449, 1365, 1318, 1138,
914, 832, 770, 755, 690 cm–1. MS: m/z = 326 [M]+· (100 %), 168.
C22H17NO2 (327.38): calcd. C 80.71, H 5.23, N 4.28; found C
80.69, H 5.20, N 4.26.
6-(Dibutylamino)flavone (12j): Oil, eluent: toluene/ethyl acetate, 8:1;
yield 42 mg (18%). 1H NMR (CDCl3): δ = 7.91 (m, 2 H, 2-H, 6-
H), 7.51 (m, 3 H, 3-H, 5-H, 4-H), 7.43 (d, J = 9.0 Hz, 1 H, 8-
H), 7.29 (d, J = 2.9 Hz, 1 H, 5-H), 7.06 (dd, J = 2.9, 9.0 Hz, 1 H,
7-H), 6.78 (s, 1 H, 3-H), 3.35 (t, J = 7.6 Hz, 4 H, 1-H), 1.60 (m,
4 H, 2-H), 1.38 (m, 4 H, 3-H), 0.97 (t, J = 7.2 Hz, 6 H, 4-H)
ppm. 13C NMR (CDCl3): δ = 178.8 (C-4), 162.5 (C-2), 148.2 (C-
8a), 146.0 (C-6), 132.3 (C-1), 131.1 (C-4), 128.9 (C-3, C-5), 126.1
(C-2, C-6), 124.7 (C-4a), 119.2 (C-7), 118.7 (C-8), 106.4 (C-5),
104.0 (C-3), 50.9 (C-1), 29.3 (C-2), 20.3 (C-3), 14.0 (C-4)
ppm. IR (KBr): ν˜ = 3060, 2925, 2928, 2870, 1639, 1614, 1566, 1500,
1453, 1363, 911, 771, 689 cm–1. MS: m/z = 349 [M]+·, 306 (100%).
C23H27NO2 (349.47): calcd. C 79.05, H 7.79, N 4.01; found C
79.07, H 7.81, N 4.02.
6-(Phenyl-methylamino)flavone (12o): Eluent: hexane/ethyl acetate,
4:1; yield 67 mg (31%); m.p. 164.5–165.5 °C. 1H NMR (CDCl3): δ
= 7.91 (m, 2 H, 2-H, 6-H), 7.67 (d, J = 2.5 Hz, 1 H, 5-H), 7.52
(m, 3 H, 3-H, 5-H, 4-H), 7.36 (m, 3 H, 8-H, 3-H, 5-H), 7.28
(dd, J = 2.9, 9.0 Hz, 1 H, 7-H), 7.10 (m, 3 H, 2-H, 6-H, 4-H),
6.81 (s, 1 H, 3-H), 3.39 (s, 3 H, NCH3) ppm. 13C NMR (CDCl3):
δ = 178.3 (C-4), 162.8 (C-2), 150.7 (C-1), 148.4 (C-8a), 146.5 (C-
6), 131.9 (C-1), 131.3 (C-4), 129.5 (C-3, C-5), 128.9 (C-3, C-
5), 126.1 (C-2, C-6), 125.5 (C-7), 124.6 (C-4a), 123.4 (C-4),
123.0 (C-2, C-6), 118.6 (C-5), 110.6 (C-8), 106.8 (C-3), 40.7
(NCH3) ppm. IR (KBr): ν˜ = 3448, 3037, 3002, 2951, 2890, 2815,
1620, 1590, 1580, 1566, 1482, 1457, 1450, 1362, 1141, 1134, 1045,
1029, 912, 832, 821, 770, 707 cm–1. MS: m/z = 327 [M]+·, 326
(100%). C22H17NO2 (327.38): calcd. C 80.71, H 5.23, N 4.28; found
C 80.69, H 5.20, N 4.28.
7-(Butylamino)flavone (18a): Eluent: toluene/ethyl acetate, 8:1; yield
157 mg (81%) from 17, 63 mg (32%) from 22; m.p. 163.5–164.5 °C.
1H NMR (CDCl3): δ = 7.96 (d, J = 8.6 Hz, 1 H, 5-H), 7.88 (m, 2
H, 2-H, 6-H), 7.49 (m, 3 H, 3-H, 5-H, 4-H), 6.69 (s, 1 H, 3-H),
6.62 (d, J = 8.6 Hz, 1 H, 6-H), 6.52 (s, 1 H, 8-H), 4.50 (s, 1 H,
NH), 3.21 (q, J = 6.8 Hz, 2 H, 1-H), 1.65 (m, 2 H, 2-H), 1.46
(m, 2 H, 3-H), 0.98 (t, J = 7.6 Hz, 3 H, 4-H) ppm. 13C NMR
(CDCl3): δ = 177.6 (C-4), 162.0 (C-2), 158.8 (C-8a), 153.2 (C-7),
132.1 (C-1), 104.0 (C-4), 128.8 (C-3, C-5), 126.5 (C-5), 125.9 (C-
2, C-6), 114.3 (C-4a), 112.9 (C-6), 107.2 (C-3), 96.2 (C-8), 43.1
(C-1), 31.1 (C-2), 20.2 (C-3), 13.8 (C-4) ppm. IR (KBr): ν˜ =
3316, 3139, 3069, 3034, 2948, 2927, 2865, 1632, 1586, 1566, 1503,
1448, 1378, 1248, 1095, 906, 824, 764, 670 cm–1. MS: m/z = 293
[M]+·, 250 (100%). C19H19NO2 (293.36): calcd. C 77.79, H 6.53, N
4.77; found C 77.76, H 6.55, N 4.78.
7-[(4-Chlorophenyl)amino]flavone (18f): Eluent: toluene/ethyl acet-
ate, 4:1; yield 126 mg (55%) from 17, 83 mg (36%) from 22; m.p.
273.5–276.5 °C. 1H NMR (CDCl3 + [D6]DMSO): δ = 8.36 (s, 1 H,
NH), 7.99 (d, J = 8.6 Hz, 1 H, 5-H), 7.90 (m, 2 H, 2-H, 6-H),
7.53 (m, 3 H, 3-H, 5-H, 4-H), 7.33 (d, J = 8.6 Hz, 2 H, 3-H,
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5-H), 7.23 (d, J = 8.6 Hz, 2 H, 2-H, 6-H), 7.09 (s, 1 H, 8-H),
7.02 (d, J = 8.6 Hz, 1 H, 6-H), 6.70 (s, 1 H, 3-H) ppm. 13C NMR
(CDCl3 + [D6]DMSO): δ = 176.7 (C-4), 161.8 (C-2), 157.6 (C-8a),
149.1 (C-7), 139.0 (C-1), 131.3 (C-1), 130.6 (C-4), 128.7 (C-2,
C-6), 128.3 (C-3, C-5), 126.9 (C-4), 126.0 (C-5), 125.4 (C-2,
C-6), 121.3 (C-2, C-6), 115.5 (C-4a), 114.2 (C-6), 106.6 (C-3),
99.2 (C-8) ppm. IR (KBr): ν˜ = 3274, 3188, 3100, 1648, 1627, 1585,
1534, 1492, 1449, 1438, 1374, 1092, 909, 813, 768, 676 cm–1. MS:
m/z = 347 [M]+· (100%), 319. C21H14ClNO2 (347.80): calcd. C
72.52, H 4.06, Cl 10.19, N 4.03; found C 72.55, H 4.10, Cl 10.21,
N 4.01.
7-Morpholinoflavone (18k): Eluent: toluene/ethyl acetate, 4:1; yield
150 mg (74%); m.p. 208–211.5 °C. 1H NMR (CDCl3): δ = 8.07 (d,
J = 9.0 Hz, 1 H, 5-H), 7.89 (m, 2 H, 2-H, 6-H), 7.51 (m, 3 H, 3-
H, 5-H, 4-H), 6.96 (dd, J = 2.2, 9.0 Hz, 1 H, 6-H), 6.83 (s, J =
2.2 Hz, 1 H, 8-H), 6.73 (s, 1 H, 3-H), 3.89 (m, 4 H, 3-H, 5-H),
3.36 (m, 4 H, 2-H, 6-H) ppm. 13C NMR (CDCl3): δ = 177.7 (C-
4), 162.6 (C-2), 158.1 (C-8a), 155.0 (C-7), 132.0 (C-1), 131.2 (C-
4), 128.9 (C-3, C-5), 126.6 (C-5), 126.0 (C-2, C-6), 115.9 (C-
4a), 112.9 (C-6), 107.4 (C-3), 100.3 (C-8), 66.4 (C-3, C-5), 47.6
(C-2, C-6) ppm. IR (KBr): ν˜ = 3432, 3060, 2963, 2855, 1632,
1592, 1573, 1511, 1494, 1448, 1383, 1239, 1124, 819, 772 cm–1. MS:
m/z = 307 [M]+· (100 %), 249, 222, 147, 91. C19H17NO3 (307.35):
calcd. C 74.25, H 5.58, N 4.56; found C 74.24, H 5.60, N 4.54.
3-Hydroxy-1-(5-bromo-2-hydroxyphenyl)-3-phenylprop-2-en-1-one
(15):
Eluent: toluene/ethyl acetate, 4:1; yield 17 mg (7.7%); m.p. 112–
115 °C. This compound was obtained as a by-product from the
reaction of tert-butylamine and 6-bromoflavone. 1H NMR
(CDCl3): δ = 15.48 (s, 1 H, 2-OH), 12.06 (s, 1 H, 3-OH), 7.96 (d,
J = 7.2 Hz, 2 H, 2-H, 6-H), 7.85 (s, 1 H, 6-H), 7.57 (d, J =
7.2 Hz, 1 H, 4-H), 7.52 (m, 3 H, 3-H, 5-H, 4-H), 6.90 (d, J =
9.0 Hz, 1 H, 3-H), 6.75 (s, 1 H, 2-H) ppm. 13C NMR (CDCl3): δ
= 194.2 (C-1), 178.4 (C-3), 161.3 (C-2), 138.3 (C-4), 133.2 (C-
1), 132.8 (C-6), 130.6 (C-4), 128.8 (C-2, C-6), 127.0 (C-3, C-
5), 120.8 (C-3), 120.3 (C-1), 110.7 (C-5), 92.1 (C-2) ppm. IR
(KBr): ν˜ = 1607, 1567, 1469, 1289, 1190, 913, 744 cm–1.
7-(Butylamino)-4-methoxyflavone (20a): Eluent: toluene/ethyl acet-
ate, 1:1; yield 178 mg (84 %); m.p. 173.5–175.5 °C. 1H NMR
(CDCl3): δ = 7.95 (d, J = 9.0 Hz, 1 H, 5-H), 7.83 (d, J = 8.6 Hz, 2
H, 2-H, 6-H), 6.99 (d, J = 8.6 Hz, 2 H, 3-H, 5-H), 6.59 (m, 2
H, 3-H, 6-H), 6.50 (d, J = 1.8 Hz, 1 H, 8-H), 4.42 (s, 1 H, NH),
3.87 (s, 3 H, 4-OCH3), 3.20 (m, 2 H, 1-H), 1.66 (m, 2 H, 2-H),
1.46 (m, 2 H, 3-H), 0.98 (t, J = 7.6 Hz, 3 H, 4-H) ppm. 13C
NMR (CDCl3): δ = 177.7 (C-4), 162.1 (C-2), 161.9 (C-4), 158.7
(C-8a), 153.0 (C-7), 127.6 (C-2, C-6), 126.5 (C-5), 124.5 (C-1),
114.4 (C-4a), 114.2 (C-3, C-5), 112.7 (C-6), 105.9 (C-3), 96.3 (C-
8), 55.4 (4-OCH3), 43.2 (C-1), 31.2 (C-2), 20.2 (C-3), 13.81
(C-4) ppm. IR (KBr): ν˜ = 3302, 2950, 2929, 2860, 1624, 1608,
1584, 1566, 1537, 1508, 1423, 1376, 1244, 1176, 1095, 909, 822,
597 cm–1. MS: m/z = 323 [M]+·, 280 (100 %), 148. C20H21NO3
(323.39): calcd. C 74.28, H 6.55, N 4.33; found C 74.25, H 6.58, N
4.35.
3-(Butylamino)flavone (24a): Yellow oil, eluent: hexane/ethyl acet-
ate, 3:1; yield 64 mg (33%). 1H NMR (CDCl3): δ = 8.24 (d, J =
7.9 Hz, 1 H, 5-H), 7.96 (d, J = 7.2 Hz, 2 H, 2-H, 6-H), 7.60 (t, J
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= 7.2 Hz, 1 H, 7-H), 7.40–7.51 (m, 4 H, 6-H, 8-H, 3-H, 5-H),
7.36 (m, 1 H, 4-H), 4.41 (s, 1 H, NH), 2.64 (t, J = 6.8 Hz, 2 H,
1-H), 1.36–1.42 (m, 2 H, 2-H), 1.21–1.29 (m, 2 H, 3-H), 0.79
(t, J = 7.5 Hz, 3 H, 4-H) ppm. 13C NMR (CDCl3): δ = 175.3 (C-
4), 155.5 (C-8a), 147.7 (C-2), 133.5 (C-4a), 132.9 (C-7), 131.6 (C-
1), 129.6 (C-5), 128.3 (C-2, C-6), 128.1 (C-3, C-5), 125.8 (C-4),
124.0 (C-6), 120.9 (C-3), 117.9 (C-8), 47.0 (C-1), 32.3 (C-2), 19.9
(C-3), 13.8 (C-4) ppm. IR (KBr): ν˜ = 3326, 2957, 2928, 2871,
2358, 1613, 1465, 1195, 757 cm–1. MS: m/z = 293 [M]+·, 250
(100%). C24H19NO2 (353.42): calcd. C 81.56, H 5.42, N 3.96; found
C 81.60, H 5.45, N 3.93.
3-N-Pyrrolidinoflavone (24d): Oil, eluent: hexane/ethyl acetate, 3:1;
yield 26 mg (13%). 1H NMR (CDCl3): δ = 8.22 (d, J = 7.9 Hz, 1
H, 5-H), 8.01 (d, J = 7.2 Hz, 2 H, 2-H, 6-H), 7.64 (m, 1 H, 7-H),
7.47–7.50 (m, 4 H, 6-H, 8-H, 3-H, 5-H), 7.37 (m, 1 H, 4-H), 3.16
(m, 4 H, 2-H, 5-H), 1.94 (m, 4 H, 3-H, 4-H) ppm. 13C NMR
(CDCl3): δ = 177.9 (C-4), 161.9 (C-8a), 155.4 (C-2), 133.1 (C-7),
132.9 (C-1), 130.4 (C-4a), 130.0 (C-5), 128.7 (C-2, C-6), 128.0
(C-3, C-5), 125.6 (C-4), 124.5 (C-6), 124.3 (C-3), 117.9 (C-8),
50.6 (C-2, C-5), 26.3 (C-3, C-4) ppm. IR (KBr): ν˜ = 3437,
2929, 2851, 1615, 1602, 1466, 1376, 1307, 1198, 754, 689 cm–1. MS:
m/z = 291 [M]+· (100 %), 248, 222, 194, 165, 120. C19H17NO2
(291.35): calcd. C 78.33, H 5.88, N 4.81; found C 78.37, H 5.90, N
4.80.
Buchwald–Hartwig Cross-Coupling of 3-Bromoflavone (23) by Mi-
crowave Activation: A mixture of 3-bromoflavone (23; 100 mg,
0.330 mmol), n-butylamine (40 μL, 0.400 mmol), NaOtBu (44 mg,
0.46 mmol), and BINAP (15 mg, 0.025 mmol) in toluene (3 mL) in
a capped vial (10 mL) was irradiated for 15 min (200 W, 110 °C).
Then the mixture was cooled, water was added (10 mL), and the
mixture was extracted with ethyl acetate (2 25 mL). The com-
bined organic layers were washed with water, and dried (magne-
sium sulfate), and the solvent was evaporated in vacuo. The crude
product was purified by column chromatography (hexane/ethyl
acetate, 4:1) to give 24a (26 mg, 27%) as a yellow oil.
Alkylation of 3-Aminoflavone (26) by Microwave Activation: A
mixture of 3-aminoflavone (26; 474 mg, 2.000 mmol), butyl brom-
ide (603 mg, 4.400 mmol), and potassium carbonate (608 mg,
4.400 mmol) in water (4 mL) was irradiated for 60 min (100 W,
120 °C) in a capped vial (10 mL). Then, the mixture was cooled
and extracted with ethyl acetate (2 25 mL). The combined or-
ganic layers were washed with water, and dried (magnesium sulf-
ate), and the solvent was evaporated in vacuo. The crude product
was purified by column chromatography (hexane/ethyl acetate, 4:1)
to give 24a (114 mg, 19%) as a yellow oil.
Ring Contraction: A mixture of 3-bromoflavone (100 mg,
0.33 mmol) and amine (0.825 mmol, 2.5 equiv.) in THF was stirred
for 1 d at ambient temperature according to the literature pro-
cedure.[45] Then the solvent was evaporated, and the crude reaction
mixture was submitted directly to a silica gel column to give the
pure product.
2-[α-(Butylamino)benzylidene]benzofuran-3(2H)-one (25a): Yellow
oil, eluent: hexane/ethyl acetate, 5:1; yield 71 mg (74%). 1H NMR
(CDCl3): δ = 10.02 (s, 1 H, NH), 7.84 (d, J = 7.6 Hz, 1 H, 5-H),
7.50 (m, 5 H, 2-H, 3-H, 4-H, 5-H, 6-H), 7.42 (t, J = 7.8 Hz, 1
H, 7-H), 7.13 (m, 2 H, 6-H, 8-H), 3.23 (t, J = 6.8 Hz, 2 H, 1-H),
1.56 (m, 2 H, 2-H), 1.38 (m, 2 H, 3-H), 0.87 (t, J = 7.3 Hz, 3
H, 4-H) ppm. 13C NMR (CDCl3): δ = 177.5, 160.8, 152.2, 132.0,
131.7, 130.2, 129.7, 128.9, 128.6, 124.7, 122.8, 121.6, 112.5, 44.2,
32.7, 29.6, 19.7, 13.6 ppm. IR (KBr): ν˜ = 3368, 3065, 2960, 2932,
2873, 1702, 1632, 1603, 1458, 1381, 1250, 755, 713 cm–1. MS: m/z
Job/Unit: O43108 /KAP1 Date: 15-12-14 12:48:59 Pages: 13
K. Kónya, D. Pajtás, A. Kiss-Szikszai, T. PatonayFULL PAPER
= 293 [M]+·, 250 (100 %). C19H19NO2 (293.36): calcd. C 77.79, H
6.53, N 4.77; found C 77.82, H 6.55, N 4.80.
General Procedure for the Synthesis of 6- and 7-(Diphenylmethyl-
eneamino)flavones (27a and 27b): A mixture of 6-bromo- (11) or
7-bromoflavone (17; 1.505 g, 5.00 mmol), BINAP (235 mg,
0.375 mmol), benzophenone imine (2; 1.10 mL, 6.00 mmol), palla-
dium acetate (55 mg, 0.250 mmol, 5 mol-%), and cesium carbonate
(2.120 g, 6.50 mmol) in xylene (30 mL) was stirred at reflux over-
night under a nitrogen atmosphere. The cooled mixture was poured
into water (100 mL), then extracted with ethyl acetate (3 25 mL).
The combined organic phases were dried with magnesium sulfate,
then the solvents were removed in vacuo. The solid residue was
triturated with a mixture of hexane (20 mL) and acetone (1 mL) to
give pure 27a or 27b as a pale yellow solid.
7-[(Diphenylmethylene)imino]flavone (27b): Yield 73%; m.p. 212–
213 °C. 1H NMR (CDCl3): δ = 7.99 (d, J = 8.6 Hz, 1 H, 5-H), 7.85
(m, 2 H, Ph), 7.77 (m, 2 H, Ph), 7.51 (m, 6 H, Ph), 7.45 (d, J =
8.6 Hz, 1 H, 6-H), 7.29 (m, 3 H, Ph), 7.17 (m, 2 H, Ph), 6.90 (s, 1
H, 8-H), 6.74 (s, 1 H, 3-H) ppm. 13C NMR (CDCl3): δ = 178.0 (C-
4), 169.5 (C=N), 162.9 (C-2), 156.8 (C-8a), 138.6 (C-7), 135.2, 137.5
(C-1), 131.8 (C-1), 132.4, 131.4, 130.0, 129.8, 129.5, 129.1, 128.3
(Ph), 126.1 (C-7), 119.4 (C-4a), 119.0 (C-5), 108.5, 107.5 (C-3, C-
8) ppm. IR (KBr): ν˜ = 3455, 3068, 1640, 1617, 1458, 1358, 1289,
1024, 910, 773, 697 cm–1. MS: m/z = 401 [M]+·, 324, 297, 221, 165
(100%), 139, 102, 77. C28H19NO2 (401.46): calcd. C 83.77, H 4.77;
found C 83.80, H 4.75. C28H19NO2 (401.46): calcd. C 83.77, H
4.77, N 3.49; found C 83.80, H 4.75, N 3.54.
General Procedure for the Synthesis of 6- and 7-Aminoflavones (28a
and 28b): [(Diphenylmethylene)imino]flavone 27a or 27b (1.466 g,
3.651 mmol) was dissolved in THF (14 mL), and HCl (6 n aq.;
9.2 mL, 18.0 mmol, 5 equiv.) was added. After 10 min, dichloro-
methane (25 mL) and water (50 mL) were added, and then the mix-
ture was stirred at room temperature overnight. Next, dichloro-
methane (10 mL) was added, upon which the reaction mixture be-
came clear. The pH was adjusted to ca. 9–10 by the addition of
saturated sodium hydrogen carbonate solution (vigorous evolution
of gas!). The product was extracted with dichloromethane (3
50 mL). The combined organic extracts were dried with magnesium
sulfate, and the solvent was evaporated in vacuo. The solid residue
was triturated with a mixture of hexane (20 mL) and acetone
(1 mL) to give pure amine 28a or 28b as a pale yellow solid.
7-Aminoflavone (28b): Yield 68%; m.p. 183–185 °C, lit. m.p.[5]
186 °C. 1H NMR (CDCl3): δ = 8.01 (d, J = 9.2 Hz, 1 H, 5-H), 7.87
(m, 2 H, 2-H, 6-H), 7.50 (m, 3 H, 3-H, 5-H, 4-H), 6.69 (m, 3
H, 3-H, 6-H, 8-H), 4.33 (br. s, 2 H, NH2) ppm. 13C NMR (CDCl3):
δ = 177.7 (C-4), 162.4 (C-2), 158.3 (C-7), 151.9 (C-8a), 132.0 (C-
1), 131.2 (C-5), 128.9 (C-3, C-5), 127.2 (C-4), 126.1 (C-2, C-
6), 115.7 (C-4a), 113.7 (C-6), 107.3 (C-3), 100.2 (C-8) ppm. IR
(KBr): ν˜ = 3462, 3332, 3194, 1633, 1586, 1569, 1450, 1388, 1370,
1248, 1186, 1026, 909, 832, 768 cm–1. MS: m/z = 237 [M]+·, 209,
180, 152, 135, 107, 79. C15H11NO2 (237.26): calcd. C 75.94, H 4.67,
N 5.90; found C 75.95, H 4.69, N 5.95.
General Method for Coupling 6- and 7-Bromoflavone with Amino
Acid Methyl Ester Hydrochlorides: Bromoflavone 11 or 17
(0.66 mmol), cesium carbonate (557 mg, 1.71 mmol), BINAP
(32 mg, 0.050 mmol), and the amino acid methyl ester hydrochlor-
ide (0.80 mmol) were mixed in dry xylene (6 mL) in an oven-dried
flask under nitrogen, and Pd(OAc)2 (7 mg, 0.032 mmol) was added.
The reaction mixture was stirred at reflux at 135 °C for 24 h in an
oil bath. The crude reaction mixture was applied directly to a silica
gel column to give the pure cross-coupled product.
www.eurjoc.org © 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 0000, 0–010
7-{[2-Phenyl-1-(methoxycarbonyl)ethyl]amino}flavone (31a): Eluent:
toluene/ethyl acetate, 2:1; yield 168 mg (64%); m.p. 171.5–173.5 °C.
1H NMR (CDCl3): δ = 8.00 (d, J = 8.6 Hz, 1 H, 5-H), 7.88 (m, 2
H, 2-H, 6-H), 7.51 (m, 3 H, 3-H, 5-H, 4-H), 7.31 (m, 3 H, 3-
H, 5-H, 4-H), 7.15 (m, 2 H, 2-H, 6-H), 6.71 (s, 1 H, 3-
H), 6.64 (dd, J = 1.8, 8.6 Hz, 1 H, 6-H), 6.54 (s, 1 H, 8-H), 4.83
(d, J = 7.9 Hz, 1 H, NH), 4.50 (m, 1 H, 1-H), 3.76 (s, 3-H, OCH3),
3.23 (m, 2 H, 2-H) ppm. 13C NMR (CDCl3): δ = 178.2 (C-4),
172.2 (COOMe), 163.2 (C-2), 158.8 (C-8a), 151.4 (C-7), 135.4 (C-
1), 131.8 (C-1), 131.5 (C-4), 129.2 (C-3, C-5), 129.0 (C-
2, C-6), 128.8 (C-3, C-5), 127.4 (C-5), 127.2 (C-4), 126.2
(C-2, C-6), 114.9 (C-4a), 113.6 (C-6), 106.8 (C-3), 97.6 (C-8), 56.8
(C-1), 52.6 (OCH3), 38.1 (C-2) ppm. IR (KBr): ν˜ = 3396, 3265,
3152, 3065, 3028, 2948, 1726, 1624, 1593, 1538, 1507, 1448, 1436,
1370, 1249, 1191, 1148, 906, 822, 766, 699 cm–1. MS: m/z = 399
[M]+·, 340, 308 (100%), 248, 221, 165, 91. C25H21NO4 (399.45):
calcd. C 75.17, H 5.30, N 3.51; found C 75.21, H 5.33, N 3.54.
This product was also obtained as a by-product from the reaction
of 6-bromoflavone (11) in 6% yield.
7-{[3-Methyl-1-(methoxycarbonyl)butyl]amino}flavone (31c): Eluent:
toluene/ethyl acetate, 2:1; yield 136 mg (56%); m.p. 152–156 °C. 1H
NMR (CDCl3): δ = 8.01 (d, J = 8.6 Hz, 1 H, 5-H), 7.89 (m, 2 H,
2-H, 6-H), 7.50 (m, 3 H, 3-H, 5-H, 4-H), 6.71 (s, 1 H, 3-H),
6.68 (dd, J = 2.1, 8.6 Hz, 1 H, 6-H), 6.56 (d, J = 2.1 Hz, 1 H, 8-
H), 4.80 (d, J = 8.6 Hz, 1 H, NH), 4.21 (m, 1 H, 1-H), 3.77 (s, 3
H, OCH3), 1.78 (m, 3 H, 2-H, 3-H), 1.02 (d, J = 6.5 Hz, 3 H,
4-H), 0.97 (d, J = 6.1 Hz, 3 H, 4-H) ppm. 13C NMR (CDCl3):
δ = 177.7 (C-4), 173.9 (COOMe), 162.4 (C-2), 158.5 (C-8a), 151.8
(C-7), 132.0 (C-1), 131.1 (C-4), 128.9 (C-3, C-5), 127.0 (C-5),
126.1 (C-2, C-6), 115.5 (C-4a), 113.1 (C-6), 107.4 (C-3), 97.5 (C-
8), 54.6 (OCH3), 52.4 (C-1), 41.8 (C-2), 24.9, 22.7 (C-4), 22.1
(C-3) ppm. IR (KBr): ν˜ = 3289, 3153, 3087, 2953, 1724, 1620,
1589, 1566, 1534, 1449, 1373, 1250, 1190, 1149, 1000, 9008, 824,
768, 686, 673 cm–1. MS: m/z = 365 [M]+·, 306 (100%), 250, 91.
C22H23NO4 (365.43): calcd. C 72.31, H 6.34, N 3.83; found C
72.35, H 6.38, N 3.85.
Supporting Information (see footnote on the first page of this arti-
cle): Experimental procedures, physical and spectroscopic data (1H
and 13C NMR, IR, and MS) for the products.
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Buchwald–Hartwig Reactions of Mono-
haloflavones
Keywords: Homogeneous catalysis / Cross-
coupling / Amination / Palladium / Amino
acids / Oxygen heterocycles
A new and efficient approach to (substi- Hartwig coupling was developed and op-
tuted) aminoflavones and hybrids of flav- timised.
ones and amino acids using Buchwald–
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